Cynthia Bosquillon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Cynthia Bosquillon has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
D.I. Pritchard
School of Pharmacy, University of Nottingham, University Park, Nottingham NG7 2RD, United Kingdom
4 shared publications- Manali Mukherjee
Department of Medicine, McMaster University
3 shared publications - Cameron Alexander
School of Pharmacy, University of Nottingham, Nottingham, UK
2 shared publications - Constanze Hilgendorf
AstraZeneca, Sweden
2 shared publications - Giuseppe Mantovani
School of Pharmacy, University of Nottingham, University Park, Nottingham, NG7 2RD, UK
2 shared publications Martin Redhead
Division of Drug Delivery & Tissue Engineering, School of Pharmacy, University of Nottingham, Nottingham, UK
2 shared publications
Latest Publications
- Open Access
- 7 July 2022
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 65 (14) , 9802-9818
Design, Synthesis, and Evaluation of Lung-Retentive Prodrugs for Extending the Lung Tissue Retention of Inhaled Drugs
A major limitation of pulmonary delivery is that drugs can exhibit suboptimal pharmacokinetic profiles resulting from rapid elimination from the pulmonary tissue. This can lead to systemic side effects and a short duration of action. A series of dibasic dipeptides attached to the poorly lung-retentive muscarinic M3 receptor antagonist piperidin-4-yl 2-hydroxy-2,2-diphenylacetate (1) through a pH-sensitive-linking group have been evaluated. Extensive optimization resulted in 1-(((R)-2-((S)-2,6-diaminohexanamido)-3,3-dimethylbutanoyl)oxy)ethyl 4-(2-hydroxy-2,2-diphenylacetoxy)piperidine-1-carboxylate (23), which combined very good in vitro stability and very high rat lung binding. Compound 23 progressed to pharmacokinetic studies in rats, where, at 24 h post dosing in the rat lung, the total lung concentration of 23 was 31.2 μM. In addition, high levels of liberated drug 1 were still detected locally, demonstrating the benefit of this novel prodrug approach for increasing the apparent pharmacokinetic half-life of drugs in the lungs following pulmonary dosing.
- 7 July 2022
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 65 (14) , 9802-9818
Open AccessDesign, Synthesis, and Evaluation of Lung-Retentive Prodrugs for Extending the Lung Tissue Retention of Inhaled Drugs
A major limitation of pulmonary delivery is that drugs can exhibit suboptimal pharmacokinetic profiles resulting from rapid elimination from the pulmonary tissue. This can lead to systemic side effects and a short duration of action. A series of dibasic dipeptides attached to the poorly lung-retentive muscarinic M3 receptor antagonist piperidin-4-yl 2-hydroxy-2,2-diphenylacetate (1) through a pH-sensitive-linking group have been evaluated. Extensive optimization resulted in 1-(((R)-2-((S)-2,6-diaminohexanamido)-3,3-dimethylbutanoyl)oxy)ethyl 4-(2-hydroxy-2,2-diphenylacetoxy)piperidine-1-carboxylate (23), which combined very good in vitro stability and very high rat lung binding. Compound 23 progressed to pharmacokinetic studies in rats, where, at 24 h post dosing in the rat lung, the total lung concentration of 23 was 31.2 μM. In addition, high levels of liberated drug 1 were still detected locally, demonstrating the benefit of this novel prodrug approach for increasing the apparent pharmacokinetic half-life of drugs in the lungs following pulmonary dosing.
- Open Access
- 11 February 2020
- Published by MDPI AG in Pharmaceutics
- Vol. 12 (2) , 145
Development of an In Vitro System to Study the Interactions of Aerosolized Drugs with Pulmonary Mucus
Mucus is the first biological component inhaled drugs encounter on their journey towards their pharmacological target in the upper airways. Yet, how mucus may influence drug disposition and efficacy in the lungs has been essentially overlooked. In this study, a simple in vitro system was developed to investigate the factors promoting drug interactions with airway mucus in physiologically relevant conditions. Thin layers of porcine tracheal mucus were prepared in Transwell® inserts and initially, the diffusion of various fluorescent dyes across those layers was monitored over time. A deposition system featuring a MicroSprayer® aerosolizer was optimized to reproducibly deliver liquid aerosols to multiple air-facing layers and then exploited to compare the impact of airway mucus on the transport of inhaled bronchodilators. Both the dyes and drugs tested were distinctly hindered by mucus with high logP compounds being the most affected. The diffusion rate of the bronchodilators across the layers was in the order: ipratropium ≈ glycopyronnium > formoterol > salbutamol > indacaterol, suggesting hydrophobicity plays an important role in their binding to mucus but is not the unique parameter involved. Testing of larger series of compounds would nevertheless be necessary to better understand the interactions of inhaled drugs with airway mucus.
- 11 February 2020
- Published by MDPI AG in Pharmaceutics
- Vol. 12 (2) , 145
Open AccessDevelopment of an In Vitro System to Study the Interactions of Aerosolized Drugs with Pulmonary Mucus
Mucus is the first biological component inhaled drugs encounter on their journey towards their pharmacological target in the upper airways. Yet, how mucus may influence drug disposition and efficacy in the lungs has been essentially overlooked. In this study, a simple in vitro system was developed to investigate the factors promoting drug interactions with airway mucus in physiologically relevant conditions. Thin layers of porcine tracheal mucus were prepared in Transwell® inserts and initially, the diffusion of various fluorescent dyes across those layers was monitored over time. A deposition system featuring a MicroSprayer® aerosolizer was optimized to reproducibly deliver liquid aerosols to multiple air-facing layers and then exploited to compare the impact of airway mucus on the transport of inhaled bronchodilators. Both the dyes and drugs tested were distinctly hindered by mucus with high logP compounds being the most affected. The diffusion rate of the bronchodilators across the layers was in the order: ipratropium ≈ glycopyronnium > formoterol > salbutamol > indacaterol, suggesting hydrophobicity plays an important role in their binding to mucus but is not the unique parameter involved. Testing of larger series of compounds would nevertheless be necessary to better understand the interactions of inhaled drugs with airway mucus.
- Open Access
- 1 August 2019
- Published by Elsevier in European Journal of Pharmaceutics and Biopharmaceutics
- Vol. 141, 210-220
In vitro investigation on the impact of airway mucus on drug dissolution and absorption at the air-epithelium interface in the lungs
- 1 August 2019
- Published by Elsevier in European Journal of Pharmaceutics and Biopharmaceutics
- Vol. 141, 210-220
Open AccessIn vitro investigation on the impact of airway mucus on drug dissolution and absorption at the air-epithelium interface in the lungs
- 7 March 2018
- Published by Springer Nature in Pharmaceutical Research
- Vol. 35 (4) , 86
Comparison of Gene Transfection and Cytotoxicity Mechanisms of Linear Poly(amidoamine) and Branched Poly(ethyleneimine) Polyplexes
This study aimed to further explore the mechanisms behind the ability of certain linear polyamidoamines (PAAs) to transfect cells with minimal cytotoxicity.
- 7 March 2018
- Published by Springer Nature in Pharmaceutical Research
- Vol. 35 (4) , 86
Comparison of Gene Transfection and Cytotoxicity Mechanisms of Linear Poly(amidoamine) and Branched Poly(ethyleneimine) Polyplexes
This study aimed to further explore the mechanisms behind the ability of certain linear polyamidoamines (PAAs) to transfect cells with minimal cytotoxicity.
- 1 October 2017
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 532 (1) , 328-336
Ipratropium is ‘luminally recycled’ by an inter-play between apical uptake and efflux transporters in Calu-3 bronchial epithelial cell layers
- 1 October 2017
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 532 (1) , 328-336
Ipratropium is ‘luminally recycled’ by an inter-play between apical uptake and efflux transporters in Calu-3 bronchial epithelial cell layers
- Open Access
- 1 January 2014
- Published by Elsevier in European Journal of Pharmaceutics and Biopharmaceutics
- Vol. 86 (1) , 74-82
Digoxin net secretory transport in bronchial epithelial cell layers is not exclusively mediated by P-glycoprotein/MDR1
- 1 January 2014
- Published by Elsevier in European Journal of Pharmaceutics and Biopharmaceutics
- Vol. 86 (1) , 74-82
Open AccessDigoxin net secretory transport in bronchial epithelial cell layers is not exclusively mediated by P-glycoprotein/MDR1
- 1 September 2013
- Published by Elsevier in Journal of Pharmacological and Toxicological Methods
- Vol. 68 (2) , 184-189
In-cell Western™ detection of organic cation transporters in bronchial epithelial cell layers cultured at an air–liquid interface on Transwell ® inserts
- 1 September 2013
- Published by Elsevier in Journal of Pharmacological and Toxicological Methods
- Vol. 68 (2) , 184-189
In-cell Western™ detection of organic cation transporters in bronchial epithelial cell layers cultured at an air–liquid interface on Transwell ® inserts
- Open Access
- 1 September 2012
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 47 (2) , 481-489
Evaluation of layers of the rat airway epithelial cell line RL-65 for permeability screening of inhaled drug candidates
- 1 September 2012
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 47 (2) , 481-489
Open AccessEvaluation of layers of the rat airway epithelial cell line RL-65 for permeability screening of inhaled drug candidates
- 21 May 2012
- Published by Royal Society of Chemistry (RSC) in Soft Matter
- Vol. 8 (25) , 6744-6754
Interactions of PEO–PPO–PEO block copolymers with lipid membranes: a computational and experimental study linking membrane lysis with polymer structure
Poly(ethylene oxide) (PEO) and poly(propylene oxide) (PPO) block co-polymers (PEO–PPO–PEO, sold as Pluronics, Poloxamers, Tetronics) are a widely used class of amphiphilic materials for different biological applications. In fact for certain members of the Pluronics series, the interactions of block segments with living cells alter the lipid membrane properties and facilitate the permeation of drugs. A fuller understanding of the molecular mechanisms underpinning these interactions is essential for ensuring their safety and efficacy in biomedical applications and to inform the design of new amphiphilic copolymers for potential use in a clinical setting. In this paper, by means of atomistic molecular dynamics simulations and membrane lysis assays, we investigate the relationship between the molecular conformations of a subset of the Pluronic copolymers (L31, L61, L62 and L64) and their haemolytic activity. Our computational studies suggest that the hydrophilic blocks in these copolymers interact with the polar head groups of lipid molecules, resulting in a predicted modification of the structure of the membranes. Parallel membrane lysis assays in human erythrocytes indicate differences in the rates of haemolysis, as a result of incubation with these polymers, that correlate well with the predicted interactions from the atomistic simulations. The computational data thus provide a putative mechanism to rationalize the available experimental data on membrane lysis by these copolymers and quantitatively agree with haemoglobin release endpoints measured when copolymers with the same molecular weight and structure as of those modelled are incubated with erythrocytes. The data further suggest some new structure–function relationships at the nanoscale that are likely to be of importance in determining the biological activity of these otherwise inert copolymers.
- 21 May 2012
- Published by Royal Society of Chemistry (RSC) in Soft Matter
- Vol. 8 (25) , 6744-6754
Interactions of PEO–PPO–PEO block copolymers with lipid membranes: a computational and experimental study linking membrane lysis with polymer structure
Poly(ethylene oxide) (PEO) and poly(propylene oxide) (PPO) block co-polymers (PEO–PPO–PEO, sold as Pluronics, Poloxamers, Tetronics) are a widely used class of amphiphilic materials for different biological applications. In fact for certain members of the Pluronics series, the interactions of block segments with living cells alter the lipid membrane properties and facilitate the permeation of drugs. A fuller understanding of the molecular mechanisms underpinning these interactions is essential for ensuring their safety and efficacy in biomedical applications and to inform the design of new amphiphilic copolymers for potential use in a clinical setting. In this paper, by means of atomistic molecular dynamics simulations and membrane lysis assays, we investigate the relationship between the molecular conformations of a subset of the Pluronic copolymers (L31, L61, L62 and L64) and their haemolytic activity. Our computational studies suggest that the hydrophilic blocks in these copolymers interact with the polar head groups of lipid molecules, resulting in a predicted modification of the structure of the membranes. Parallel membrane lysis assays in human erythrocytes indicate differences in the rates of haemolysis, as a result of incubation with these polymers, that correlate well with the predicted interactions from the atomistic simulations. The computational data thus provide a putative mechanism to rationalize the available experimental data on membrane lysis by these copolymers and quantitatively agree with haemoglobin release endpoints measured when copolymers with the same molecular weight and structure as of those modelled are incubated with erythrocytes. The data further suggest some new structure–function relationships at the nanoscale that are likely to be of importance in determining the biological activity of these otherwise inert copolymers.